

REPORT TO THE LEGISLATURE  
Pursuant to P.A. 119 of 2023  
Article 2, Section 607  
MAT Clinics  
FY24 – 3<sup>rd</sup> Quarter

Sec. 607 (2) The department must submit quarterly reports on the status of establishment and operation of medication assisted treatment clinics. Reports shall include, but not be limited to, all of the following:

- (a) Site locations selected.
- (b) Staffing levels.
- (c) Expenditures on staffing and supplies, including oral and injectable medications.
- (d) Number of prisoners treated.
- (e) Number of prisoners requiring treatment but not yet receiving treatment.

Michigan Department of Corrections has 26 correctional facilities prescribing naltrexone and 13 of those correctional facilities are currently prescribing buprenorphine products for Medications for Assisted Treatment (MAT) for those diagnosed with an Opioid Use Disorder. MDOC has begun prescribing buprenorphine products at three additional correctional facilities this quarter. Increasing the total number of buprenorphine sites from 10 at the end of quarter two to 13 by the end of quarter three. The information below is for the third quarter of FY24 and will be updated on the fourth quarter report as we have not received all the expenses for June due to pending invoices. May expenses have been included in the totals below, however, the invoices will not receive payment until June.

Site locations selected	Buprenorphine Sites	13
	Naltrexone Sites	26
	New MAT sites established	3
Staffing levels	Filled MAT Positions	16
	Vacant MAT Positions	1
Expenditures on staffing	State of Michigan:	\$35,026.29
	Temp:	\$166,594.76
	<b>TOTAL COST:</b>	<b><u>\$201,621.05</u></b>
Expenditures on supplies, including oral and injectable medications	*Sublocade:	\$1,150,190.63
	Suboxone:	\$33,014.74
	Naltrexone:	\$35,007.86
	<b>TOTAL COST:</b>	<b><u>\$1,218,213.23</u></b>
	<i>*(<math>\\$2.5</math> million dollars were used from the Opioid Settlement Fund to pay for Sublocade in Q1)</i>	
Number of prisoners treated	Number of inmates that have received at least 1 dose of MAT medication	
	<b>TOTAL:</b>	<b><u>1,439</u></b>

Number of prisoners requiring treatment but not yet receiving treatment	<b>TOTAL:</b> <u><b>2,807</b></u>
---	-----------------------------------

Below is the updated expenses and information from quarter two as we received all invoices after the quarter two report was submitted.

Site locations selected	Buprenorphine Sites	10
	Naltrexone Sites	26
	New MAT sites established	0
Staffing levels	Filled MAT Positions	13
	Vacant MAT Positions	4
Expenditures on staffing	State of Michigan:	\$67,246.53
	Temp:	\$291,500.39
	<b>TOTAL COST:</b>	<b><u>\$358,746.92</u></b>
Expenditures on supplies, including oral and injectable medications	*Sublocade:	\$2,297,875.35
	Suboxone:	\$41,625.79
	Naltrexone:	\$41,280.73
	<b>TOTAL COST:</b>	<b><u>\$2,380,781.87</u></b>
	<i>*(<math>\\$2.5</math> million dollars were used from the Opioid Settlement Fund to pay for Sublocade in Q1)</i>	
Number of prisoners treated	Number of inmates that have received at least 1 dose of MAT medication	
	<b>TOTAL:</b>	<b><u>1,481</u></b>
Number of prisoners requiring treatment but not yet receiving treatment	<b>TOTAL:</b>	<b><u>2,529</u></b>